Study of Etanercept in the Treatment of Psoriasis in Adult Subjects

- Active guttate, erythrodermic, or pustular psoriasis at the time of
the baseline visit - Any adverse event or infection at the time of the baseline visit or at
any time during the previous etanercept psoriasis study which, in the opinion of Amgen or
the Investigator, would preclude participation in the study - Presence of a serious
infection less than or equal to 30 days prior to the baseline visit - Evidence of skin
conditions at the baseline visit (e.g., eczema) that would interfere with evaluations of
the effect of investigational product on psoriasis - Previous receipt of anti-TNF agent(s)
other than etanercept - Receipt of any investigational product(s), other than etanercept,
less than or equal to 30 days prior to first dose of investigational product in this study
- Receipt of anti-CD4 or diphtheria IL-2 fusion protein less than or equal to 24 weeks
prior to first dose of investigational product in this study - Psoralen and ultraviolet A
(PUVA) light therapy less than or equal to 14 days prior to first dose of investigational
product in this study - Ultraviolet A (UVA) light therapy less than or equal to 14 days
prior to first dose of investigational product in this study - Ultraviolet B (UVB) light
therapy less than or equal to 14 days prior to first dose of investigational product in
this study - Receipt of any other systemic psoriasis therapy or oral or parenteral
corticosteroids less than or equal to 14 days prior to first dose of investigational
product in this study - Pregnant or breast-feeding females - Significant concurrent medical
conditions prior to enrollment, including: uncontrolled hypertension (defined as systolic
blood pressure measurement of greater than 180 mm Hg or an untreated diastolic blood
pressure of greater than 110 mm Hg); myocardial infarction less than or equal to 52 weeks
prior to baseline visit; unstable angina pectoris; uncompensated congestive heart failure;
severe pulmonary disease requiring hospitalization or supplemental oxygen therapy;
diagnosis of multiple sclerosis or any other demyelinating disease; insulin-dependent
diabetes mellitus; history of cancer (other than in-situ cervical cancer or resected
cutaneous basal cell or squamous cell carcinoma) less than or equal to 5 years prior to
administration of first dose of investigational product; open cutaneous ulcers; known human
immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg) or hepatitis C virus
(HCV) positive; any condition that might cause this study to be detrimental to the subject,
in the judgment of the investigator.